169 related articles for article (PubMed ID: 36606606)
21. Fertility preservation options in breast cancer patients.
Kasum M; von Wolff M; Franulić D; Čehić E; Klepac-Pulanić T; Orešković S; Juras J
Gynecol Endocrinol; 2015; 31(11):846-51. PubMed ID: 26370157
[TBL] [Abstract][Full Text] [Related]
22. Outcome of ovarian stimulation for oocyte cryopreservation in women with Turner syndrome.
Talaulikar VS; Conway GS; Pimblett A; Davies MC
Fertil Steril; 2019 Mar; 111(3):505-509. PubMed ID: 30598170
[TBL] [Abstract][Full Text] [Related]
23. Ovarian stimulation in the luteal phase: systematic review and meta-analysis.
Boots CE; Meister M; Cooper AR; Hardi A; Jungheim ES
J Assist Reprod Genet; 2016 Aug; 33(8):971-80. PubMed ID: 27146151
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
Hum Reprod; 2020 Apr; 35(4):929-938. PubMed ID: 32313940
[TBL] [Abstract][Full Text] [Related]
25. Ovarian stimulation is a safe and effective fertility preservation option in the adolescent and young adult population.
Manuel SL; Moravek MB; Confino R; Smith KN; Lawson AK; Klock SC; Pavone ME
J Assist Reprod Genet; 2020 Mar; 37(3):699-708. PubMed ID: 31828481
[TBL] [Abstract][Full Text] [Related]
26. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.
Abir R; Ben-Aharon I; Garor R; Yaniv I; Ash S; Stemmer SM; Ben-Haroush A; Freud E; Kravarusic D; Sapir O; Fisch B
Hum Reprod; 2016 Apr; 31(4):750-62. PubMed ID: 26848188
[TBL] [Abstract][Full Text] [Related]
27. Fertility preservation with random-start controlled ovarian stimulation and embryo cryopreservation for early pregnancy-associated breast cancer.
Pereira N; Kligman I; Hunt R; Kopparam R; Wahmann B; Rosenwaks Z
Gynecol Endocrinol; 2019 Mar; 35(3):214-216. PubMed ID: 30403906
[TBL] [Abstract][Full Text] [Related]
28. Oocyte cryopreservation for fertility preservation in women with ovarian endometriosis.
Kim SJ; Kim SK; Lee JR; Suh CS; Kim SH
Reprod Biomed Online; 2020 Jun; 40(6):827-834. PubMed ID: 32295746
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of ovarian stimulation in the follicular and luteal phases of the menstrual cycle in cancer patients.
Nazarenko TA; Martirosyan YO; Birukova AM; Korneeva IE; Sokolova J; Khubaeva DG
Gynecol Endocrinol; 2021; 37(sup1):13-16. PubMed ID: 34937510
[TBL] [Abstract][Full Text] [Related]
30. Medical and elective fertility preservation: impact of removal of the experimental label from oocyte cryopreservation.
Schon SB; Shapiro M; Gracia C; Senapati S
J Assist Reprod Genet; 2017 Sep; 34(9):1207-1215. PubMed ID: 28656539
[TBL] [Abstract][Full Text] [Related]
31. Double ovarian stimulation (DuoStim) protocol for fertility preservation in female oncology patients.
Tsampras N; Gould D; Fitzgerald CT
Hum Fertil (Camb); 2017 Dec; 20(4):248-253. PubMed ID: 28423955
[TBL] [Abstract][Full Text] [Related]
32. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
[TBL] [Abstract][Full Text] [Related]
33. Fertility Preservation for Adolescent and Young Adult Transmen: A Case Series and Insights on Oocyte Cryopreservation.
Barrett F; Shaw J; Blakemore JK; Fino ME
Front Endocrinol (Lausanne); 2022; 13():873508. PubMed ID: 35685214
[TBL] [Abstract][Full Text] [Related]
34. Random-start ovarian stimulation in women desiring elective cryopreservation of oocytes.
Pereira N; Voskuilen-Gonzalez A; Hancock K; Lekovich JP; Schattman GL; Rosenwaks Z
Reprod Biomed Online; 2017 Oct; 35(4):400-406. PubMed ID: 28647355
[TBL] [Abstract][Full Text] [Related]
35. Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
Quinn MM; Cakmak H; Letourneau JM; Cedars MI; Rosen MP
Hum Reprod; 2017 Mar; 32(3):568-574. PubMed ID: 28122888
[TBL] [Abstract][Full Text] [Related]
36. Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible.
Sermondade N; Grynberg M; Comtet M; Valdelievre C; Sifer C; Sonigo C
Sci Rep; 2020 Oct; 10(1):18555. PubMed ID: 33122722
[TBL] [Abstract][Full Text] [Related]
37. Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases.
Saito S; Yamada M; Yano R; Takahashi K; Ebara A; Sakanaka H; Matsumoto M; Ishimaru T; Utsuno H; Matsuzawa Y; Ooka R; Fukuoka M; Akashi K; Kamijo S; Hamatani T; Tanaka M
J Ovarian Res; 2023 Aug; 16(1):159. PubMed ID: 37563616
[TBL] [Abstract][Full Text] [Related]
38. Follicular steroidogenesis in random start protocols for oocyte cryopreservation.
Galati G; Somigliana E; Ciaffaglione M; Reschini M; Serra N; Sanzani E; Viganò P; Polledri E; Fustinoni S; Muzii L; Filippi F
J Assist Reprod Genet; 2023 Sep; 40(9):2149-2156. PubMed ID: 37439869
[TBL] [Abstract][Full Text] [Related]
39. The Significance of Planned Fertility Preservation for Women With Endometrioma Before an Expected Ovarian Cystectomy.
Hong YH; Lee HK; Kim SK; Lee JR; Suh CS
Front Endocrinol (Lausanne); 2021; 12():794117. PubMed ID: 34975763
[TBL] [Abstract][Full Text] [Related]
40. Maximize the safety and efficacy of fertility preservation by random start/dual ovarian stimulation for early breast cancer patients.
Young SR; Chang YE; Yang WV; Lu BJ; Chou SY; Chen CH
Taiwan J Obstet Gynecol; 2023 Mar; 62(2):330-333. PubMed ID: 36965903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
